Furthermore, the combination of these two products has been demonstrated to inhibit the PD-1/PD-L1 protein expression leading to synergetic downregulation of the protein expression of PD-L1 and NF-κB, and reduction in tumor growth [59]. The gene discussed is CD274; the disease is neoplasm.